methylthio-2 pyridinecarboxylate-4 de methyle | 74470-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: methylthio-2 pyridinecarboxylate-4 de methyle
• 英文别名: methyl 2-(methylthio)isonicotinate；2-methylthioisonicotinic acid methyl ester；Methyl 2-(methylsulfanyl)pyridine-4-carboxylate；methyl 2-methylsulfanylpyridine-4-carboxylate
• CAS: 74470-39-6
• 化学式: C₈H₉NO₂S
• 分子量: 183.231
• InChiKey: IOWBEZLBCKONCE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methylthio-2 pyridinecarboxylate-4 de methyle 在 sodium periodate 、 rhodium(III) chloride hydrate 、 1,3-双(二苯基膦)丙烷 、 nickel dichloride 、 锌 作用下， 以 四氯化碳 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 22.0h， 生成 2-苯基吡啶-4-羧酸甲酯
  参考文献：
  名称：

  二氟甲基2-吡啶基砜的镍催化芳族碘化物的还原2-吡啶化

  摘要：

  芳基碘化物和二氟甲基2-吡啶砜（2-PySO 2 CF 2 H）之间新型的镍催化还原性交叉偶联可通过选择性的C（sp 2）-S形成C（sp 2）-C（sp 2）键键断裂，表明2-PySO 2 CF 2 H试剂具有新的反应活性。该方法采用容易获得的镍催化剂和砜作为亲电子交联偶合剂，可在温和的反应条件下轻松获得联芳基，而无需提前生成芳基金属试剂。

  DOI：

  10.1021/acs.orglett.0c03939
• 作为产物：
  描述：

  2-氯异烟酸甲酯 、 sodium thiomethoxide 以 甲醇 为溶剂， 反应 3.0h， 以22%的产率得到methylthio-2 pyridinecarboxylate-4 de methyle
  参考文献：
  名称：

  NOVEL COMPOUND HAVING 4-PYRIDYLALKYLTHIO GROUP AS SUBSTITUENT

  摘要：

  公开号：

  EP1602647B1

文献信息

• Compounds having a 4-pyridylalkylthio group as a substituent
  申请人：Honda Takahiro

  公开号：US20090286786A1

  公开（公告）日：2009-11-19

  A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is benzene or an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxy, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.

  一种具有以下式[I]或其药学上可接受的盐的化合物：其中，A是苯或一种芳香五元杂环，该芳香五元杂环可以选择性地与环烷环融合；B是一种烷基；R1和R2是氢、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基，或R1和R2结合形成一个杂环；X和Y是氢、卤素、羟基、烷氧基、芳基氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基；p为0、1或2；q为0或1。该化合物用于治疗与血管生成或血管通透性增加有关的疾病。
• COMPOUNDS HAVING 4-PYRIDYLALKYLTHIO GROUP AS A SUBSTITUENT
  申请人：Honda Takahiro

  公开号：US20120202817A1

  公开（公告）日：2012-08-09

  A compound having the following formula [I] or a pharmaceutically acceptable salt thereof: wherein A is an aromatic five-membered heterocycle which optionally is fused with a cycloalkane ring; B is an alkylene; R 1 and R 2 are hydrogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, heterocycle, amino, alkylamino, arylamino or acyl, or R 1 and R 2 join together to form a heterocycle; X and Y are hydrogen, halogen, hydroxyl, alkoxy, aryloxy, alkyl, cycloalkyl, aryl, mercapto, alkylthio, arylthio, carboxyl, an ester of carboxyl, an amide of carboxyl, cyano or nitro; p is 0, 1 or 2; and q is 0 or 1. The compound is useful for treating diseases in which angiogenesis or augmentation of vascular permeability is involved.

  以下化合物式[I]或其药学上可接受的盐：其中A是一种芳香五元杂环，可选择与环烷基融合；B是一种烷基；R1和R2是氢、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、杂环、氨基、烷基氨基、芳基氨基或酰基，或R1和R2结合形成一个杂环；X和Y是氢、卤素、羟基、烷氧基、芳氧基、烷基、环烷基、芳基、巯基、烷硫基、芳硫基、羧基、羧酸酯、羧酰胺、氰基或硝基；p为0、1或2；q为0或1。该化合物可用于治疗涉及血管生成或增强血管通透性的疾病。
• Novel compounds having 4-pyridylalkylthio group as substituent
  申请人：Santen Pharmaceutical Co., Ltd

  公开号：EP2527326B1

  公开（公告）日：2014-10-08
• 6,5-BICYCLIC OCTAHYDROPYRROLOPYRIDINE OREXIN RECEPTOR ANTAGONISTS
  申请人：Kim Ronald M.

  公开号：US20170320874A1

  公开（公告）日：2017-11-09

  The present invention is directed to 6,5-bicyclic octahydropyrrolopyridine compounds which are antagonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.
• US7534802B2
  申请人：——

  公开号：US7534802B2

  公开（公告）日：2009-05-19